Table 3. Univariate (log-rank) and... | American Society of Hematology

Table 3.

Univariate (log-rank) and multivariate (Cox regression) analyses of patients with NPM1+ ELN favorable-risk AML

OS
Variable	Univariate			Multivariate
Variable	HR	95% CI	P value	HR	95% CI	P value
Age ≥60 y at diagnosis	2.63	1.47-4.69	.001	0.94	0.45-1.95	.869
Type of AML∗
sAML	1.05	0.13-8.42	.964	0.83	0.10-7.01	.868
Therapy-related AML	5.84	0.64-53.13	.117	5.70	0.61-52.81	.126
FLT3-ITD status	1.31	0.67-2.58	.434	1.27	0.61-2.64	.528
Mutation burden >3	1.21	0.74-1.98	.438	1.07	0.62-1.87	.810
sMut	2.97	1.77-4.96	<.001	2.95	1.56-5.59	<.001
Frontline treatment†
Nonintensive	3.67	2.16-6.24	<.001	2.71	1.44-5.13	.002
No treatment	57.66	14.48-229.5	<.001	84.03	16.76-421.3	<.001
Received allo-HCT	0.31	0.18-0.53	<.001	0.36	0.20-0.66	.001

OS
Variable	Univariate			Multivariate
Variable	HR	95% CI	P value	HR	95% CI	P value
Age ≥60 y at diagnosis	2.63	1.47-4.69	.001	0.94	0.45-1.95	.869
Type of AML∗
sAML	1.05	0.13-8.42	.964	0.83	0.10-7.01	.868
Therapy-related AML	5.84	0.64-53.13	.117	5.70	0.61-52.81	.126
FLT3-ITD status	1.31	0.67-2.58	.434	1.27	0.61-2.64	.528
Mutation burden >3	1.21	0.74-1.98	.438	1.07	0.62-1.87	.810
sMut	2.97	1.77-4.96	<.001	2.95	1.56-5.59	<.001
Frontline treatment†
Nonintensive	3.67	2.16-6.24	<.001	2.71	1.44-5.13	.002
No treatment	57.66	14.48-229.5	<.001	84.03	16.76-421.3	<.001
Received allo-HCT	0.31	0.18-0.53	<.001	0.36	0.20-0.66	.001

sMut: ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2.

Reference level is de novo AML.

Reference level is intensive treatment.